10.28.08
Avid Bioservices, Inc. has signed a manufacturing supply agreement with Catalyst Biosciences to produce clinical-grade material for Catalyst's drug candidate, CB 813, a new version of factor VIIa for the treatment of acute bleeding in hemophilia patients.
Under the terms of the agreement, Avid will begin manufacturing drug supply under cGMP regulations and provide cell bank preparation, process development, and preparation of the manufacturing portion of the NDA. Further details were not disclosed.
“This agreement with Catalyst Biosciences for their lead clinical candidate is the most recent example of the traction we are gaining as a trusted provider of cGMP manufacturing services, as well as our broad capabilities as a provider of valuable ancillary services," said Steven W. King, president of Avid. "We are delighted to be working with the talented Catalyst team and their promising engineered protease technology.”
"Avid's expertise in the scale-up and manufacture of clinical-grade biotechnology therapeutics and their strong customer orientation made them a good choice for Catalyst,” said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences.
Under the terms of the agreement, Avid will begin manufacturing drug supply under cGMP regulations and provide cell bank preparation, process development, and preparation of the manufacturing portion of the NDA. Further details were not disclosed.
“This agreement with Catalyst Biosciences for their lead clinical candidate is the most recent example of the traction we are gaining as a trusted provider of cGMP manufacturing services, as well as our broad capabilities as a provider of valuable ancillary services," said Steven W. King, president of Avid. "We are delighted to be working with the talented Catalyst team and their promising engineered protease technology.”
"Avid's expertise in the scale-up and manufacture of clinical-grade biotechnology therapeutics and their strong customer orientation made them a good choice for Catalyst,” said Nassim Usman, Ph.D., chief executive officer of Catalyst Biosciences.